Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 4, 937–947 (1 December 2004) | doi:10.1038/nrc1503
Targeting the mitogen-activated protein kinase cascade to treat cancer
&
Abstract
The RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
